The women's health company reported first-quarter 2019 operating results.
News & Analysis: TherapeuticsMD, Inc.
TXMD earnings call for the period ending March 31, 2019.
Are intrepid short-sellers taking advantage of misguided enthusiasm?
TXMD earnings call for the period ending December 31, 2018.
The company impressed investors with more encouraging sales figures for its recently launched dyspareunia treatment.
Traders are feeling giddy after management shared the bull case for owning its stock at an important investor conference.
An FDA approval usually triggers a rally, so why are shares down today?
With new drug applications under review at the moment, these 3 biotech stocks could surge in the weeks ahead.
The pharma company had a busy month of updates and progress.
Can these red-hot drug stocks keep the momentum going?